Prust04's May/June 2025 Portfolio Review

I wrote and then forgot to publish my May summary, so I’m combining May and June, which have been great months for my Portfolio. Some of the company notes might be a little clunky due to the combination. Looking at my year, despite all the chaos I really just had a terrible March and it’s been a long road to recover to what is now a decent gain for the year.

May was a hell of a month with many of my companies up 20% or more. I was up almost 25% which got me back to green for the year. Much of this seemed to be due to the easing of the macro/tariff situation, but I had some very promising earnings reports as well.

June was more of a mixed bag but I had some more huge gains with half of my positions to lead to another really solid month. I’m not quite back to my February ATHs but I’m approaching it.

I have 14 positions now, which is a few more than I’d like and I’ll probably cut a few over earnings which will kick off for me at the end of July. I’ll cover each company below and how I reacted to earnings as well as any decisions that were made.

Here are my results to date and current portfolio:

JAN: -1.54%
FEB: +2.77%
MAR: -14.77%
APR: +7.91%
MAY: +24.92
JUN: +11.48%
YTD: +14.68%

(I think the huge off-hours drop from Jan 31 to Feb 1 is not reflected in the above monthly changes)

What I Sold & Why:
NU: -3% May

Another frustrating earnings report where things seem to be going pretty well, key metrics continue to be impressive but also slipping, and I can’t imagine the share price improving unless they were to accelerate revenue or net income growth. After digesting the conversation on the board and the seemingly immovable stock price over the past, I decided to sell out as I believe my money can be better used elsewhere.

What I Trimmed & Why:

INOD: +4.7% May, +29% June
At earnings, they reported a drop in revenue from Q4 to Q1 which should not happen at this size of a company, and only reiterated their guide. I trimmed it from a tier 1 to a tier 3 position in case this is just a blip on the radar, so we will see next earnings if I keep it around. The stock price has recovered some but there has been no news that I’ve seen.

PAY: +17.7% May, -14% June
I wrote about my feelings for Paymentus’ earnings when they dropped. They are predictable sandbaggers, actually guiding to ~5% QoQ drops in revenue pretty consistently, before beating by a wide margin. However, their actual QoQ numbers are dropping quickly: 17% to 11% to 7% to most recently, 3%. So in anticipation of the trend continuing, I sold half my position after earnings and they are now in my third tier. I will also say that I’m really just following numbers with this company vs. my other holding where I understand more about the actual business and the trends surrounding it.

NTRA: +4.4% May, +8% June
YoY Revenue growth slowed from 53% to 36% and they still are net income negative, and also my 2nd most expensive stock when comparing revenue growth to EV/Sales. So I trimmed them back to a tier 3 position as well, selling half my shares.

KRYS: -25.7% May
For a small company, they had a big miss with a drop in revenue in Q1. A shame really because they have great margins and profitability, but I sold out right after earnings.

What I Added To And Why

NBIS: +63% May, +50% June
Big thanks to the board and in particular @Jonathan1 for clueing us in. I doubled my initial position before earnings and then tripled it right after they reported. The annual revenue guide was staggering and represents enormous acceleration in the next few quarters. They moved their way into my #2 position after these two tremendous months.

SEZL: +38.6% Since Purchase in May, +68% June
I was late to the SEZL game even with all the board chatter. My mistake! I wrote it off as a late entry into BNPL but they are continuing to accelerate revenue and income quarter after quarter, and even though the stock has taken off, they are reasonably placed in my affordability rankings.

CRMD: -4.6% Since Purchase in May, +1.5% June
Thank you @ryshab for bringing them to the board! I took a small position after seeing the revenue growth, high margins and profitability. It will stay as a starter position until next earnings since as WPR noted, they did guide for a drop in revenue.

ETON: +1.42% Since Purchase in June
Another from @ryshab, this stacks very high in my growth affordability rankings (#2) so I took a small position that I will add to most likely during earnings.

NVMI: +23% Since Purchase in June
This one is a little pricier but the major metrics are accelerating and so I wanted to get in before it rises much further.

Untouched

HIMS: +70.9% May, -12% June
I thought it was a great quarter and really blew my personal expectations out of the water with 111% revenue growth YoY. They explained that the outlook was temporary. I am not concerned about the fallout with Novo, as I believe it proved that they are scaring the big pharma players. I’m following the numbers and the very confident leadership team.

PGY: +49.3% May, +31% June
I wrote about Pagaya’s earnings, which gave it a modest boost, but the bigger news may have been the latest ABS deal which expands funding capacity by $1B in the POS vertical. Hopefully this gives them no problem getting back to 25% or greater revenue growth moving forward, even with a conservative, profitability-focused tone right now. I’m hoping after a couple more positive earnings results, the market stops discounting this company, who is at 1.8x EV/Sales. They’ve had a great couple of months in share price, hitting a 52-wk high, but have a ton more room to run if they continue to execute come earnings season. I do have some long calls here but I don’t report them to my overall performance.

APP: +44.5% May, -10% June
Another strong earnings report, while they announced they are selling their less-profitable apps division as well. This will make them even more of a money making machine, and eCommerce hasn’t even ramped yet. Happy with them as a tier 1 position even though they are my most “expensive” stock based on rev growth and EV/Sales. I’m not concerned with any of the short reports as they are largely arguments against the entire digital advertising industry. They are annoying, however, for the stock price temporarily.

DCTH: +34.4% May, -16.10% June
Still growing revenue quickly and are on track with their treatment centers, and are now participating in the Medicare Drug Rebate program to accelerate adoption. Staying in Tier 1 until something changes, although the pullback in June has it hovering in the middle of my portfolio.

ALAB: +38.6% May, Flat in June
Earnings saw 144% revenue growth and a strong raise. I have full confidence in ALAB even though the price got demolished in Q1. With the strong NVDA earnings, hopefully people realize that the AI run is nowhere close to over, and neither is ALAB growth. They seem to be expecting a big 2nd half.

UPST: -1.3% May, +37% June
I was super encouraged by earnings and was pretty shocked they actually dropped in price in May. But it has started to increase again in June. In their seasonally slow Q1, they beat earnings by 6.5% which added up to 66% revenue growth, increased Net Income even in the slow quarter, while putting forward solid raises. With a solid beat they’ll be at almost 80% revenue growth…it seems like the market is still recalling getting burnt due to the initial interest rate chaos, but this seems like a different company since then.

NVDA: +24% May, +17% June
I’m sure we all read about their great earnings report, so I won’t cover it much. It’s nice to see it finally hit another ATH, although I can’t imagine it doubling from here like I can with many of my other stocks. But it’s a nice foundational stock I don’t have plans of selling while they keep delivering.

That’s all. Thank you for reading and as always, thank you to all the board contributors for their knowledge sharing. Best of luck in July.

47 Likes

Prust

You mentioned how one of your holdings was positioned in you “growth and affordability” rankings. I am interested in the metrics you use for both (particularly affordability), the source of the data and how you update your database.

As some here, may recall, my consideration for entry begins with ranking level which is based on numerically weighted performance against a number of metric targets.

Thanks for any info.

Gray

2 Likes

@Graydrake it’s not a very sophisticated formula I’m afraid. I have a Koyfin watchlist set up that looks at YoY Revenue Growth Rate, divided by EV/Sales, which gives me a numerical value. For my portfolio that range stretches from a value of 145 (Delcath) to 2 (Applovin). Higher values theoretically represent a discounted price based on how fast they are growing.

I also keep an eye on Net Income and am roughly prioritizing companies that are both profitable and growing on that side, but it’s not baked into the formula yet. Perhaps I’ll look into that.

Please feel free to poke holes.

6 Likes

Thank you. There value in using a numerical means to assess the relative price you are paying for growth. Jamin Ball’s substack Clouded Judgment provides some great charts on defining the massive differences the market is willing to pay for revenue growth. I feel this type of valuation metric works over time, but PLTR continues to run with valuation metrics well out of of my buy range – so at least for this ticker the market is not considering valuation important.

Gray

1 Like

For sure. And I’ve been burnt exiting stocks that I felt where too highly valued for the relative growth rate (e.g. Axon), as well as for waiting for price to catch up with valuation (e.g. PGY, although it’s finally starting to gain momentum). For this reason, I rarely use my calculation to fully exit a position anymore, but rather use it to help make weighting decisions in my portfolio.

7 Likes

Thanks for the shout out prust04 on Nebius. I continue to hold very high hopes for this company and even though there will be volatility of course, I can easily see this doubling or tripling even from here (their new ATH).

I held Pagaya for such a long time. I stayed with it through the ups and downs (mainly downs) over 2 plus years. Then just 3 months ago I sold all of PGY at a loss. Of course, shortly after, it started it’s rise and I missed out!!

Still Saul teaches us not to worry about stocks we have sold which is sage advice. And I can’t be too sad because I put all of the proceeds from my PGY sale into increasing my large Nebius holding. So not too shabby!

Best,

Jonathan

14 Likes

I was wondering where the number for 3% qoq is coming from? I’m showing Q4 to Q1, going from 257.9M to 275.2M which would be a 6.7% increase.

I was recently re-reading the transcripts for the companies I own and PAY’s transcript stood out as one of the most enthusiastic. Whether it’s the lowered OpEx, record FCF, uptick in large enterprises, and increased transaction volume.

From my point of view this company could be valued at 20B, but it’s valued at 4B right now. The reason I say that is there’s many SaaS companies around that 300M quarterly revenue that carry this valuation. I think the market is still lumping Paymentus in the transactional kiosk payments space similar to a Shift4 and Lightspeed. A lot of investors still have never heard of Paymentus, which I like because the opportunity is largely unrecognized by the market currently.

12 Likes

@wpr101 you’re right and my mistake, in my sheet I often project out the next quarter based on trends of how well my companies have been beating their own guidance. The 3% is a forward projection for Q2 based on their beat % dropping from Q3-Q1.

6 Likes